Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study objective was to determine if liver injury develops in alcoholic patients during or following 5 days of therapeutic acetaminophen dosing. Volunteers were recruited from two community detoxification centers to take either acetaminophen (4g/day) or placebo for 5 consecutive days. All subjects were monitored an additional two days following the dosing period. The primary measures were aminotransferase measures taken at baseline and Days 2, 4, 6 and 7. We hypothesized that there would be no difference in aminotransferase means between the groups at any study period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | acetaminophen 4 g/day |
|
| 2 | Placebo Comparator | placebo undistinguishable from active drug |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| acetaminophen (4g/day) | Drug |
| ||
| placebo |
| Measure | Description | Time Frame |
|---|---|---|
| group mean aminotransferase measures | ||
| mean change in aminotransferase measures between study groups |
| Measure | Description | Time Frame |
|---|---|---|
| proportion of subjects that develop an aminotransferase level greater than the upper limit of reference range | ||
| proportion of subjects that develop hepatotoxicity (ALT>1000 IU/L) | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard C Dart, MD, PhD | Denver Health/Rocky Mountain Poison & Drug Center | Principal Investigator |
| Bruna Brands, PhD | Centre for Addiction and Mental Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Denver CARES | Denver | Colorado | 80204 | United States | ||
| Centre for Addiction and Mental Health |
Not provided
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000082 | Acetaminophen |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| proportion of subjects that develop drug induced liver injury |
| Toronto |
| Ontario |
| M5S 2S1 |
| Canada |
| Aniline Compounds |
| D000588 | Amines |